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Manually curated and harmonised 
transcriptomics datasets of 
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patients
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We present manually curated transcriptomics data of psoriasis and atopic dermatitis patients 
retrieved from the NCBI Gene Expression Omnibus and EBI ArrayExpress repositories. We collected 
39 transcriptomics datasets, deriving from DNA microarrays and RNA-Sequencing technologies, for a 
total of 1677 samples. We provide quality-checked, homogenised and preprocessed gene expression 
matrices and their corresponding metadata tables along with the estimated surrogate variables. 
These data represent a ready-made valuable source of knowledge for translational researchers in the 
dermatology field.
Background & Summary
Psoriasis (PSO) and Atopic dermatitis (AD) are among the most common inflammatory skin disorders associated 
with immunologic impairment. While the first signs of AD tend to appear in the early childhood, the manifes-
tation of PSO is most common during the third decade of life1. Both the diseases have a substantial negative 
impact on the quality of life of affected patients. Although a number of therapeutic approaches have been devel-
oped in the last two decades to mitigate PSO and AD symptoms, their pathophysiology is still not completely 
understood2,3. AD is believed to be driven by epidermal barrier disruption, activation of specific T-cell subsets, 
and dysbiosis of the commensal skin microbiome2 while psoriatic inflammation is sustained by uncontrolled 
responses of the innate and adaptive cutaneous immune system, which lead to intense keratinocyte proliferation 
and dysfunctional differentiation4.
Transcriptomics technologies, such as DNA microarray and RNA Sequencing (RNA-Seq), have been used to 
characterise the molecular alterations of human diseases5, including PSO and AD. To date, only marginal efforts 
have been carried out in order to collect, quality-check and harmonize PSO- and AD-related transcriptomics data 
in order to make them easily reusable by the research community. Therefore, the motivation behind this study 
was to create a source of ready-to-use data of gene expression profiles of PSO and AD patients derived from both 
DNA microarray and RNA-Seq publicly available datasets.
The preprocessed and harmonized microarray data provided in this study were collected from the NCBI 
Gene Expression Omnibus (GEO) and EBI ArrayExpress public repositories, while the RNA-Seq datasets were 
retrieved from the European Nucleotide Archive (ENA). Overall, 26 microarrays datasets were collected, for a 
total of 991 samples, 632 of which from patients affected by psoriasis and 70 by atopic dermatitis. Some of the 
microarray datasets contain samples collected from patients affected by other skin diseases such as psoriatic 
arthritis, psoriasis sebaceous hyperplasia, palmoplantar pustulosis, lichen planus and discoid lupus. These data-
sets were generated with commercially available Affymetrix and Agilent platforms. All of the analytical steps 
performed in this work were carried out through the use of the eUtopia software6. We also retrieved 13 RNA-Seq 
datasets, for a total of 686 samples, 392 of which from patients affected by psoriasis and 94 by atopic dermatitis. 
RNA-seq data were mostly produced through Illumina platforms, while a minority of datasets were produced 
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through other platforms. All the datasets underwent meta-data curation and harmonisation, data quality check 
and preprocessing with standardised procedures. The curation and harmonisation of the meta-data consisted in 
the definition and usage of a common data model for all of the collected datasets. The data models, to which the 
raw meta-data were mapped to, are reported in the data dictionary files (enclosed with the preprocessed data). 
The data dictionary describes all the variables reported in the final metadata tables. For each variable, the descrip-
tion, type and allowed values are reported. At the same time, this work is aimed at homogenising the preproc-
essing procedures in order to improve the comparability of the gene expression data across different studies and 
platforms. Therefore, in this work we provide meta-data tables, along with the inferred surrogate batch variables, 
as well as the preprocessed gene expression estimates.
Our analysis significantly increases the FAIRness7 of publicly available PSO and AD transcriptomics data and 
represents a valuable “ready-to-use” resource available to the scientific community.
Methods
Microarray data. Data collection and homogenization. Transcriptomics data generated by DNA microar-
rays of psoriasis and atopic dermatitis patients were retrieved from NCBI GEO8 (GEO - https://www.ncbi.nlm.
nih.gov/geo/) and EBI ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) repositories by using the R packages 
GEOquery9 and ArrayExpress10,11, respectively. For each dataset, a table specifying the disease (psoriasis/atopic 
dermatitis) and the origin of biopsy (lesional/non-lesional sample) in addition to other phenotypic information 
was also retrieved. Since the phenotypic information was heterogeneous across the datasets, rigorous harmoni-
zation procedure was performed. The GEO and Array Express identifiers of the retrieved datasets are reported 
in Tables 1–3.
Data quality check. The retrieved datasets were thoroughly quality checked. In particular, each sample was 
evaluated by visual inspection of the array pseudo-images, quality check reports and density plots of probe inten-
sities by using the eUTOPIA software6. Further, outlier detection step, based on the sample distributions, was 
performed within each dataset by using ad hoc R scripts (see Code Availability section).
Moreover, for the Affymetrix datasets, outlier samples were detected by computing the Normalized Unscaled 
Standard Error (NUSE)12 and the Relative Log Expression (RLE)12 from the affyPLM v1.64.0 R package, and the 
RNA degradation curves (RNADeg)13 from the affy v1.64.0 R package (Fig. 1).
The distributions of the values of these three metrics were investigated by means of boxplots and the sample 
outlierness was evaluated for each measure based on the data distribution. Eventually, a concordance outlierness 
score was computed across the three metrics. In particular, a sample was removed from the analysis if considered 
an outlier in at least two out of three metrics, one of them being the RNA degradation curve.
Normalization. Data normalization was performed by using the eUTOPIA software. Affymetrixbased studies 
were normalized by using the justRMA from the R affy v1.66.0 package14. Agilent-based studies were quantile 
normalized with the normalizeQuantiles function from the limma v3.44.3 package15.
Surrogate variable analysis. In order to investigate the effect of unknown batches that might mask biological 
variability, Surrogate Variable Analysis (SVA) was performed with the eUtopia software, which implements the 
sva R package16. The analysis was performed by using origin of biopsy or diagnosis as variable of interest. The 
other biological variables (if present and if not confounded with the variable of interest) were used as covariates6. 
The estimated surrogate variables for each dataset are included in the meta-data tables.
Probe annotation. Custom annotation files (CDF files) were downloaded from Brainarray (http://brainarray.
mbni.med.umich.edu/Brainarray/Database/CustomCDF/CDF\_download.asp) for Affymetrix-based microar-
rays. The latest version of Agilent probe annotation was retrieved from the Agilent website (https: //earray.chem.
agilent.com/earray/). The probesets were mapped to the Ensembl gene IDs and the expression matrix was aggre-
gated by computing the median of the expression of the Agilent probes mapping to the same Ensembl transcript 
ID. The entire DNA microarray data preprocessing is depicted in Fig. 1.
RNA Sequencing data. Data collection and homogenization. Raw files in “.fastq” format were retrieved 
from the European Nucleotide Archive (ENA). Along with the raw data files, the metadata tables reporting the 
samplewise clinical features for each dataset were also collected. As for the DNA microarray data, the meta-




# of included 
samples PMID Technology Platform
GSE16161 16 20004782 Microarray GPL570
GSE32924 28 21388663 Microarray GPL570
GSE120721 50 25567045 Microarray GPL570
GSE65832 40 25840722 RNA-Seq GPL10999
Table 1. DNA microarray and RNA-Sequencing datasets of Atopic Dermatitis samples.
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information for each dataset is reported along with the gene expression tables. GEO and ENA identifiers of the 
retrieved datasets are reported in Tables 1–3.
Quality control. All the RNA-Seq datasets underwent quality check through the use of FastQC v0.11.7 (https://
www.bioinformatics.babraham.ac.uk/projects/fastq c/). Reads were trimmed for low-quality ends in addition to 
adapters removal by TrimGalore v0.4.4_dev (http://www.bioinformatics.babraham.ac.uk/ projects/trim_galore/). 
In particular, the reads were trimmed if the Phred score was lower than 20 and discarded if the number of unde-
tected nucleotides was greater than 50. The trimmed and adapter-clipped raw files were further quality checked 
with FastQC v0.11.7.
Read alignment. RNA Sequencing reads were then aligned against the human reference genome assembly 
GRCh38. The alignment was performed through the use of the HISAT2 algorithm17,18 using the genome indexes 
built for usage with HISAT2 (retrieved from https://ccb.jhu.edu/software/hisat2/manual.shtml).
Psoriasis
Dataset ID
# of included 
samples PMID Technology Platform
E-MTAB-3201 19 26086874 Microarray GPL571
GSE2737 8 16283139 Microarray GPL91
GSE6710 25 16858420 Microarray GPL96
GSE13355 173 19169254 Microarray GPL570
GSE14905 75 18648529 Microarray GPL570
GSE30999 151 22763790 Microarray GPL570
GSE34248 24 23308107 Microarray GPL570
GSE41662 46 23308107 Microarray GPL570
GSE50790 8 22479649 Microarray GPL570
GSE52471 38 23771123 Microarray GPL571
GSE58121 18 25058585 Microarray GPL14550
GSE61281 52 25243786 Microarray GPL6480
GSE67853 24 26763436 Microarray GPL570
GSE68923 5 28570274 Microarray GPL13607
GSE68924 5 28570274 Microarray GPL13607
GSE68937 6 28570274 Microarray GPL13607
GSE68939 5 28570274 Microarray GPL13607
GSE78097 31 27185339 Microarray GPL570
GSE80047 50 27152848 Microarray GPL13158
GSE82140 8 27312025 Microarray GPL17692
GSE83582 93 27448749 Microarray GPL19983
GSE106087 6 Unpublished Microarray GPL15207
GSE41745 6 21850022 RNA-Seq GPL10999
GSE47944 84 24909886 RNA-Seq GPL11154
GSE54456 174 24441097 RNA-Seq GPL9052
GSE63979 42 5723451 RNA-Seq GPL9052
GSE67785 28 26251673 RNA-Seq GPL10999
GSE74697 52 27793094 RNA-Seq GPL16791
GSE83645 25 29031600 RNA-Seq GPL10999
GSE107871 24 29273799 RNA-Seq GPL10999
GSE117405 28 30054515 RNA-Seq GPL11154
GSE123785 19 31539532 RNA-Seq GPL18573
GSE123786 16 31539532 RNA-Seq GPL11154
Table 3. DNA microarray and RNA-Sequencing datasets of Psoriasis samples.
Atopic Dermatitis and Psoriasis
Dataset ID
# of included 
samples PMID Technology Platform
GSE75890 27 26841714 Microarray GPL17692
GSE121212 147 30641038 RNA-Seq GPL16791
Table 2. DNA microarray and RNA-Sequencing datasets of Psoriasis and Atopic Dermatitis samples.
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Conversions between.sam and.bam file formats, sorting and extraction of uniquely mapped reads were per-
formed through the use of samtools version 1.8-27-g089626219.
Read counts extraction. Transcript abundance was computed by using the featurecounts function from the 
Rsubread v2.2.3 R package20. To accomplish this task, the Gencode version 31 annotation was downloaded from 
https://www.gencodegenes.org, and then utilized for read counts extraction.
Low counts filtering. In order to filter out the transcripts with low expression levels in all the samples of each 
dataset, the proportion test strategy was used as implemented in the function filtered.data of the R package 
NOISeq v2.31.021.
Normalization. RNASeq expression data were normalized using the upper quantile method22 implemented in 
the R package NOISeq v2.31.0.
Surrogate Variable Analysis. As for the DNA microarray data, in order to identify unknown sources of technical 
variability, a Surrogate Variable Analysis (SVA) was performed through the use of the svaseq function imple-
mented in the sva v3.36.0 R/Bioconductor package16. The analysis was performed by using disease state or diag-
nosis as variable of interest. The other biological variables (if present and if not confounded with the variable of 
interest) were used as covariates6. The estimated surrogate variables for each dataset are included in the meta-data 
tables, along with the gene expression tables. The entire RNA-Seq data preprocessing is depicted in Fig. 2.
Data Records
The complete list of DNA microarray and RNA Sequencing datasets discussed in this work is reported in 
Tables 1–3. All the preprocessed transcriptomics data, along with harmonised meta-data, were submitted to 
Zenodo23.
Technical Validation
DNA microarray and RNA-Seq data are linked to clinical meta-data, reporting multiple information such as gen-
der, age or the treatment (including e.g. drug dose). Additionally, sample meta-data is recorded, such as the tissue 
type a sample was taken from, or whether the tissue derives from a lesional or nonlesional sample.
In order to ensure that the data is recorded in a consistent and well-formed way, we created data dictionaries 
describing each of these variables. The data dictionaries contain detailed information describing the content of 
a variable, the data type (numeric, categorical, text, date, etc), the allowed values of categorical data or ranges of 
numeric variables.
The data was validated by checking compliance with the rules encoded in the data dictionaries. Data that 
was found not to comply with the rules was manually curated by consulting the original data sources. In fact, a 
large proportion of the datasets were found not to meet the requirements encoded in the data dictionaries. For 
Fig. 1 DNA microarray data preprocessing pipeline.
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instance, big heterogeneity was found in the description of the skin status. “Involved skin”, “psoriatic skin” were 
reported in order to describe the “lesional” status of the skin. “Normal”, “ctrl”, “Non-involved skin of healthy 
individual” were used to describe the “healthy control” samples. Yet, to define the gender, “m”, “f ”, “male” and 
“female” were used across the datasets. All of these variables were mapped to the allowed values reported in the 
data dictionaries to improve the comparability across the datasets.
Usage Notes
The transcriptomics data presented in this article is an unprecedented source of preprocessed, harmonized, 
“ready-to-use” and FAIR datasets, made available to the scientific community. Data derived from both DNA 
microarray and RNASeq technologies can be exploited in order to uncover the molecular mechanisms under-
lying psoriasis and atopic dermatitis. Differential expression analysis can be carried for instance by the limma 
package15 for the microarray data, and the edgeR24, DESeq 225 or NOISeq21 packages for RNA-Seq data, respec-
tively. Functional analysis of differentially expressed genes can be performed by using FunMappOne26, the R/
Bioconductor package ReactomePA27 or Ingenuity Pathway Analysis (Qiagen, http://www.ingenuity.com/prod-
ucts/ipa). The inference and analysis of co-expression networks can be performed, for instance, by using the 
INfORM tool28. Altogether, these analyses can aid the stratification of PSO and AD patients, the identification of 
relevant biomarkers and novel therapeutic targets.
Code availability
R scripts for the analysis of DNA microarray and RNA-Seq transcriptomics data are available for download at: 
https://github.com/Greco-Lab/psoriasis-dermatitis-analysis.
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